Paola Pdb Di Benedetto

List of Publications by Year in Descending Order

65 papers	1,839 citations	26 h-index	41 g-index
67 ext. papers	2,254 ext. citations	5.6 avg, IF	4.47 L-index

#	Paper	IF	Citations
65	Association Between Minor Salivary Gland Biopsy During Sjögren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. *Frontiers in Immunology*, **2021**, 12, 686457	8.4	3
64	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. *Scientific Reports*, **2021**, 11, 12455	4.9	3
63	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. *Arthritis Research and Therapy*, **2021**, 23, 213	5.7	4
62	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. *Frontiers in Immunology*, **2020**, 11, 1130	8.4	51
61	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. *Arthritis Research and Therapy*, **2020**, 22, 127	5.7	11
60	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. *PLoS ONE*, **2020**, 15, e0235326	3.7	15
59	Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences. *Annals of the Rheumatic Diseases*, **2020**, 79, 1152-1155	2.4	23
58	Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. *Scientific Reports*, **2020**, 10, 12232	4.9	21
57	Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. *Autoimmunity Reviews*, **2020**, 19, 102662	13.6	4
56	Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences' by Ruscitti ' by Chen. *Annals of the Rheumatic Diseases*, **2020**,	2.4	0
55	Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon. *Annals of the Rheumatic Diseases*, **2020**, 79, e53	2.4	3
54	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326		
53	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326		
52	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326		
51	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326		
50	Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases. *Autoimmunity Reviews*, **2019**, 18, 102369	13.6	38
49	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. *PLoS ONE*, **2019**, 14, e0211142	3.7	8

48	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. *Scientific Reports*, **2019**, 9, 7144	4.9	12
47	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. *Scientific Reports*, **2019**, 9, 4589	4.9	5
46	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). *Molecular Medicine Reports*, **2019**, 20, 1488-1498	2.9	7
45	IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study. *Medicine (United States)*, **2019**, 98, e14587	1.8	21
44	The Vessels Contribute to Fibrosis in Systemic Sclerosis. *Israel Medical Association Journal*, **2019**, 21, 471-474	0.9	7
43	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. *Modern Rheumatology*, **2018**, 28, 922-932	3.3	11
42	H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. *Clinical and Experimental Immunology*, **2018**, 191, 220-228	6.2	27
41	The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes. *Reviews on Recent Clinical Trials*, **2018**, 13, 210-214	1.2	16
40	Cardiovascular Disease in Primary Sjögren's Syndrome. *Reviews on Recent Clinical Trials*, **2018**, 13, 164-169	1.2	3
39	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. *Journal of Immunology Research*, **2018**, 2018, 8410182	4.5	16
38	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. *Arthritis Research and Therapy*, **2018**, 20, 223	5.7	19
37	Interstitial lung disease in systemic sclerosis: current and future treatment. *Rheumatology International*, **2017**, 37, 853-863	3.6	55
36	Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2017**, 76, 1123-1132	2.4	140
35	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. *International Journal of Rheumatic Diseases*, **2017**, 20, 1247-1260	2.3	10
34	PTP4A1 promotes TGF signaling and fibrosis in systemic sclerosis. *Nature Communications*, **2017**, 8, 1060	17.4	26
33	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. *Expert Review of Clinical Immunology*, **2017**, 13, 1041-1047	5.1	27
32	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management.	13.6	84
31	Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systematic Sclerosis. *Cell Transplantation*, **2017**, 26, 841-854	4	23

30	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. *Clinical Rheumatology*, **2017**, 36, 251-260	3.9	16
29	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. *Autoimmunity Reviews*, **2017**, 16, 16-21	13.6	49
28	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. *PLoS ONE*, **2017**, 12, e0170108	3.7	32
27	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. *Journal of Rheumatology*, **2016**, 43, 1340-9	4.1	33
26	Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al. *Arthritis and Rheumatology*, **2016**, 68, 2348	9.5	
25	IL-1 at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. *Expert Review of Clinical Immunology*, **2016**, 12, 849-55	5.1	39
24	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. *Archives of Medical Science*, **2016**, 12, 828-43	2.9	5
23	H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. *Clinical and Experimental Immunology*, **2016**, 186, 30-8	6.2	30
22	The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis. *Clinical and Experimental Immunology*, **2016**, 183, 397-404	6.2	23
21	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. *Clinical and Experimental Immunology*, **2016**, 184, 284-92	6.2	28
20	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. *BMC Medicine*, **2016**, 14, 194	11.4	85
19	Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. *Clinical and Experimental Rheumatology*, **2016**, 34, 1123-1124	2.2	4
18	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. *Cytotherapy*, **2015**, 17, 832-49	4.8	14
17	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. *Journal of Rheumatology*, **2015**, 42, 1808-16	4.1	60
16	Macitentan inhibits the transforming growth factor- profibrotic action, blocking the signaling mediated by the ETR/TRI complex in systemic sclerosis dermal fibroblasts. *Arthritis Research and Therapy*, **2015**, 17, 247	5.7	18
15	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. *Clinical and Experimental Immunology*, **2015**, 182, 35-44	6.2	78
14	The role of IL-1 in the bone loss during rheumatic diseases. *Mediators of Inflammation*, **2015**, 2015, 782382	4.3	103
13	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. *Autoimmunity Reviews*, **2015**, 14, 429-37	13.6	38

12	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren?s syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. *Seminars in Arthritis and Rheumatism*, **2014**, 44, 314-24	5.3	54
11	Potential of stem cells in the treatment of rheumatic disease. *International Journal of Clinical Rheumatology*, **2014**, 9, 183-195	1.5	
10	A3.8 Association between clinical, histopathological and molecular features in primary Sjögrens Syndrome: a retrospective study. *Annals of the Rheumatic Diseases*, **2014**, 73, A45.1-A45	2.4	
9	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. *Fibrogenesis and Tissue Repair*, **2014**, 7, 13		19
8	Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. *Arthritis Research and Therapy*, **2014**, 16, 442	5.7	36
7	Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. *Angiogenesis*, **2013**, 16, 595-607	10.6	54
6	Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. *Clinical and Experimental Immunology*, **2013**, 173, 195-206	6.2	52
5	Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. *Expert Review of Clinical Immunology*, **2013**, 9, 441-52	5.1	12
4	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. *Arthritis Research and Therapy*, **2013**, 15, R172	5.7	112
3	Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. *British Journal of Pharmacology*, **2012**, 165, 436-54	8.6	36
2	Cellular players in angiogenesis during the course of systemic sclerosis. *Autoimmunity Reviews*, **2011**, 10, 641-6	13.6	39
1	Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. *Journal of Medicinal Chemistry*, **2007**, 50, 3984-4002	8.3	77